Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
- PMID: 19396150
- DOI: 10.1038/modpathol.2009.61
Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
Abstract
The human epidermal growth factor receptor 2 (HER2) oncoprotein is overexpressed in about 20% of breast cancers, with HER2 gene amplification responsible for protein overexpression in the vast majority of patients. A subset of breast cancers have chromosome 17 aneusomy, due to either 17 monosomy (a single copy of chromosome 17) or polysomy (increased copy numbers of chromosome 17). Although HER2 overexpression is an established adverse prognostic factor in breast cancer, the role of unamplified chromosome 17 polysomy is uncertain and there is a paucity of literature on the correlation of chromosome 17 aneusomy with important prognostic and predictive pathologic factors in invasive breast carcinoma. Furthermore, while patients showing HER2 amplification with or without polysomy 17 are treated with trastuzumab with or without other chemotherapy, treatment of patients with unamplified chromosome 17 polysomy is not well defined. Currently most of these patients are treated similar to patients with neither amplification nor 17 polysomy. The aim of this study was to compare some prognostic and predictive factors in invasive breast carcinoma in patients with unamplified chromosome 17 polysomy with that seen in cases with HER2 gene amplification and those with neither amplification or polysomy. We found that invasive breast carcinomas with unamplified chromosome 17 polysomy are associated with several adverse prognostic indicators such as a higher nuclear grade, mitotic activity, Nottingham score, histologic grade, tumor stage, and greater estrogen receptor negativity with a trend towards the amplified group, in contrast to patients with neither amplification or polysomy. Although most patients with unamplified 17 polysomy have a 2+ equivocal score on immunohistochemistry, a minority has a 3+ positive score. An increased adverse role for unamplified polysomy along with 3+ protein expression in some patients supports the idea that these patients should be considered for therapy with trastuzumab and/or anthracyclines.
Similar articles
-
Correlation of immunohistochemical expression of p53 with unamplified chromosome 17 polysomy in invasive breast carcinoma.Appl Immunohistochem Mol Morphol. 2011 Jan;19(1):28-32. doi: 10.1097/PAI.0b013e3181e9bb6f. Appl Immunohistochem Mol Morphol. 2011. PMID: 20823770
-
Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.J Clin Pathol. 2013 Dec;66(12):1070-5. doi: 10.1136/jclinpath-2013-201506. Epub 2013 Aug 1. J Clin Pathol. 2013. PMID: 23908451
-
[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Zhonghua Bing Li Xue Za Zhi. 2006. PMID: 17134563 Chinese.
-
Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.Tumour Biol. 2016 Jul;37(7):8665-72. doi: 10.1007/s13277-015-4657-7. Epub 2016 Jan 6. Tumour Biol. 2016. PMID: 26738861
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Mod Pathol. 2014. PMID: 23807776 Review.
Cited by
-
Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy.Eur J Breast Health. 2021 Mar 31;17(2):128-136. doi: 10.4274/ejbh.galenos.2021.2021-2-9. eCollection 2021 Apr. Eur J Breast Health. 2021. PMID: 33870112 Free PMC article.
-
Impact of chromosome 17 centromere copy number increase on patient survival and human epidermal growth factor receptor 2 expression in gastric adenocarcinoma.Oncol Lett. 2021 Feb;21(2):142. doi: 10.3892/ol.2020.12403. Epub 2020 Dec 21. Oncol Lett. 2021. PMID: 33552261 Free PMC article.
-
Centromere 17 copy number gain reflects chromosomal instability in breast cancer.Sci Rep. 2019 Nov 29;9(1):17968. doi: 10.1038/s41598-019-54471-w. Sci Rep. 2019. PMID: 31784614 Free PMC article.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3581-3589. doi: 10.31557/APJCP.2018.19.12.3581. Asian Pac J Cancer Prev. 2018. PMID: 30583686 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous